Hans Biomed

Hans Biomed Current Liabilities

The Current Liabilities of Hans Biomed (042520.KQ) as of Nov 1, 2026 is 7.39 B KRW. In the previous year, Current Liabilities was 4.25 B KRW — a change of 73.86% (higher).

Current Liabilities

7.39 BKRW

YoY

73.86%

Last updated:

Current Liabilities of Hans Biomed is 2025 7.39 B KRW. Current Liabilities of Hans Biomed was 2024 4.25 B KRW. It decreases by 73.86% higher compared to the previous year.

The Hans Biomed Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
20.05 B KRW
Jan 1, 2019
24.18 B KRW
Jan 1, 2020
28.09 B KRW
Jan 1, 2021
60.99 B KRW
Jan 1, 2022
74.44 B KRW
Jan 1, 2023
4.02 B KRW
Jan 1, 2024
4.25 B KRW
Jan 1, 2025
7.39 B KRW
The Hans Biomed Current Liabilities history
YEARCurrent LiabilitiesYoY
7.39 BKRW+73.86%
4.25 BKRW+5.69%
4.02 BKRW-94.60%
74.44 BKRW+22.06%
60.99 BKRW+117.12%
28.09 BKRW+16.19%
24.18 BKRW+20.57%
20.05 BKRW-13.42%
23.16 BKRW+114.50%
10.80 BKRW+95.36%
5.53 BKRW+86.23%
2.97 BKRW+31.73%
2.25 BKRW+55.78%
1.45 BKRW-79.05%
6.90 BKRW+307.50%
1.69 BKRW-35.59%
2.63 BKRW+3.50%
2.54 BKRW+17.20%
2.17 BKRW-22.54%
2.80 BKRW+15.42%
2.43 BKRW+9.88%
2.21 BKRW+17.90%
1.87 BKRW+63.49%
1.15 BKRW-35.60%
1.78 BKRW+44.32%
1.23 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hans Biomed Stock analysis

What does Hans Biomed do? Hans Biomed Corp manufactures and sells graft material and silicon products under brand names SureDerm, BellaGen, and GPS for skin-implant materials used in burn treatment and skin graft. The company offers bone-implant materials including allogeneic bones, xenogenous bones, and synthetic bones under SureFuse, ExFuse, and SureOss for dentistry and orthopedic applications. Silicone products such as BellaGel and Scar Clinic are utilized for scar treatment and breast implants. The firm also provides hair transplanters as part of its product portfolio. Skin-implant materials under SureDerm, BellaGen, and GPS are purchased by medical facilities for burn treatment and skin graft procedures. Bone-implant materials under SureFuse, ExFuse, and SureOss are bought by dental and orthopedic clinics for various surgical needs. Silicone products BellaGel and Scar Clinic are acquired by healthcare providers for scar management and breast implant surgeries. Hair transplanters are sold to medical institutions requiring such equipment. The company's primary revenue streams come from the sale of skin-implant materials, bone-implant materials, and silicone products across medical, dental, and orthopedic sectors. Medical facilities, dental clinics, and orthopedic practices represent key customer segments. Brand names SureDerm, BellaGen, GPS, SureFuse, ExFuse, SureOss, BellaGel, and Scar Clinic drive product differentiation and market positioning in the healthcare industry. Hans Biomed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hans Biomed stock

Current Liabilities of Hans Biomed is 7.39 B KRW in 2025.

Current Liabilities of Hans Biomed changed from 4.25 B KRW to 7.39 B KRW, representing a 73.86% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Hans Biomed since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Hans Biomed historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Hans Biomed

All Key Metrics — Hans Biomed